Thus, for ERα-positive BRCA1/2-related BC, chemoprevention, oophorectomy, and adjuvant treatment with selective estrogen receptor modulators or aromatase inhibitors to reduce risk of contralateral breast cancer are promising options. This evidence concerns the gene ESR1 and breast cancer.